Search - tctmd.com

Displaying 21 - 31 of 31

Sort: Relevancy | Date

Presentation THT 2026

Left Atrial To Coronary Sinus Shunting In Heart Failure With Mildly Reduced Or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 3-Year Results

Presenter: Benjamin Hibbert

March 03, 2026

Presentation THT 2026

Microaxial Flow Pump Use in Different Phenotypes of Cardiogenic Shock – a Secondary Analysis of the DanGer Shock Trial

Presenter: Elric Zweck

March 03, 2026

Presentation THT 2026

AI in the Trenches: Lessons From Clinical Trial Optimization

Presenter: Jonathan Cunningham

March 02, 2026

Presentation THT 2026

Autologous Cell Therapy May Curb Pathological Ventricular Remodeling in Chronic Ischemic HFrEF Patients Selected for Favorable Cell Characteristics - Late Breaking Echocardiography Results from the CardiAMP HF trial

Presenter: Amish Raval

March 02, 2026

Presentation CTO 2026

What Do the Trials Say?

Presenter: Ajay J. Kirtane

February 14, 2026

Presentation CTO 2026

What Do the Trials Say (PROCTOR, STAR, INVEST)?

Presenter: James C. Spratt

February 14, 2026

Presentation CTO 2026

What Do the Trials Say (PROTECT, NOBLE 10yrs, etc)?

Presenter: Jeffrey W. Moses

February 13, 2026

Presentation CTO 2026

What Do the Trials Say (ECLIPSE, SHORT-CUT, etc)?

Presenter: Binita Shah

February 13, 2026

1. Cost Awareness and Trusting Your Mentors With Suzanne Baron, MD

Podcast Hearts & Minds

1. Suzanne Baron, MD, on Cost Awareness and Listening to Mentors

January 14, 2026

Partner Content

Clinical Evidence Shaping Personalized DAPT Strategies

January 23, 2026

Partner Content

The Real Impact of Paradise™ Ultrasound RDN: Real Data. Real Durability. Real Difference

January 22, 2026

Advertisement

Left Atrial To Coronary Sinus Shunting In Heart Failure With Mildly Reduced Or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 3-Year Results

Microaxial Flow Pump Use in Different Phenotypes of Cardiogenic Shock – a Secondary Analysis of the DanGer Shock Trial

AI in the Trenches: Lessons From Clinical Trial Optimization

Autologous Cell Therapy May Curb Pathological Ventricular Remodeling in Chronic Ischemic HFrEF Patients Selected for Favorable Cell Characteristics - Late Breaking Echocardiography Results from the CardiAMP HF trial

What Do the Trials Say?

What Do the Trials Say (PROCTOR, STAR, INVEST)?

What Do the Trials Say (PROTECT, NOBLE 10yrs, etc)?

What Do the Trials Say (ECLIPSE, SHORT-CUT, etc)?

1. Suzanne Baron, MD, on Cost Awareness and Listening to Mentors

Clinical Evidence Shaping Personalized DAPT Strategies

The Real Impact of Paradise™ Ultrasound RDN: Real Data. Real Durability. Real Difference

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content